Evidence map›Paper›PMID 34612023›Full record

ArticleCancer medicine2021

Novel human melanoma brain metastasis models in athymic nude fox1

Henrik A Svendsen, Torstein R Meling, Vigdis Nygaard, Stein Waagene, Hege Russnes, Siri Juell, Siril G Rogne, Jens Pahnke, Eirik Helseth, Øystein Fodstad and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Towards updated understanding of brain metastasis.American journal of cancer research · 2022
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 5 countries.

Henrik A SvendsenInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.ORCID 0000-0002-4169-5801
Torstein R MelingInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.ORCID 0000-0001-6595-0873
Vigdis NygaardDepartment of Tumor Biology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Stein WaageneDepartment of Tumor Biology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Hege RussnesDepartment of Pathology, Oslo University Hospital, Oslo, Norway.
Siri JuellDepartment of Tumor Biology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Siril G RogneDepartment of Neurosurgery, Oslo University Hospital, Oslo, Norway.
Jens PahnkeInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.ORCID 0000-0001-7355-4213
Eirik HelsethInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Øystein FodstadInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Gunhild M MaelandsmoDepartment of Tumor Biology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
Oslo University Hospital · NOUniversity of Geneva · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMalignant melanomas frequently metastasize to the brain, but metastases in the cerebellum are underrepresented compared with metastases in the cerebrum.

methodsWe established animal models by injecting intracardially in athymic nude fox1

resultsUsing magnetic resonance imaging (MRI), metastases were first detected after a mean of 34.5 days. Mean survival time was 59.6 days for the mice in the HM86 group and significantly shorter (43.7 days) for HM19-injected animals (p < 0.001). In the HM86 group, the first detectable metastasis was located in the cerebellum in 15/55 (29%) mice compared with none in the HM19 group (p < 0.001). At sacrifice, cerebellar metastases were found in 34/55 (63%) HM86-injected mice compared with 1/53 (2%) in the HM19-injected (p < 0.001) mice. At that time, all mice in both groups had detectable metastases in the cerebrum. Comparing macroscopic and histologic appearances of the brain metastases with their clinical counterparts, the cell line-based tumors had kept their original morphologic characteristics.

conclusionsThe present work demonstrates that human brain-metastatic melanoma cells injected intracardially in mice had retained inherent characteristics also in reproducing interaction with subtle microenvironmental brain tissue compartment-specific features. The models offer new possibilities for investigating tumor- and host-associated factors involved in determining tissue specificity of brain metastasis.

Indexed as

AnimalsBrain NeoplasmsCell Line, TumorDisease Models, AnimalFemaleHumansMagnetic Resonance ImagingMelanomaMiceMice, NudeNeoplasm MetastasisSkin NeoplasmsTumor Cells, Culturedathymic nude fox1nu micebrain metastasis modelhuman melanomasite specificitytissue-specific metastasis

Identifiers

PMID34612023
PMCPMC8633237
OpenAlexW3202188384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.